Inclisiran in a real-world single-center registry of patients with very high atherosclerotic cardiovascular risk
{{output}}
Background: A mean relative 50 % reduction of LDL cholesterol (LDLc) levels was observed in randomized studies in patients treated with inclisiran, a small-interfering-RNA therapeutic agent that reduces hepatic synthesis of PCSK9... ...
